Greig, Nigel H.

Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease

Fang, E. F., Hou, Y., Palikaras, K., Adriaanse, B. A., Kerr, J. S., Yang, B., Lautrup, S., Hasan-Olive, M. M., Caponio, D., Dan, X., et al. (2019) · Nature Neuroscience

Alzheimer's disease research and treatmentsAutophagy in Disease and Therapy

Cited by 1,740

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 889

Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms

Kerr, J. S., Adriaanse, B. A., Greig, N. H., Mattson, M. P., Cader, M. Z., Bohr, V. A., & Fang, E. F. (2017) · Trends in Neurosciences

Alzheimer's disease research and treatmentsAutophagy in Disease and Therapy

Cited by 870

Running-induced systemic cathepsin B secretion is associated with memory function

Moon, H. Y., Becke, A., Berron, D., Becker, B., Sah, N., Benoni, G., Janke, E., Lubejko, S. T., Greig, N. H., Mattison, J. A., et al. (2016) · Cell Metabolism

Neurogenesis and neuroplasticity mechanismsNerve injury and regeneration

Cited by 628

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences

Parkinson's Disease Mechanisms and TreatmentsNeuroprotection in Cerebral Ischemia

Cited by 589

An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript

Rogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S. S., Utsuki, T., et al. (2002) · Journal of Biological Chemistry

Iron Metabolism and DisordersRNA and protein synthesis mechanisms

Cited by 551

Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4

Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics

Alzheimer's disease research and treatmentsDiabetes Treatment and Management

Cited by 380

Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 347

Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease

Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 331

Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus

Mushtaq, G., Greig, N., Khan, J., & Kamal, M. (2014) · CNS & Neurological Disorders - Drug Targets

Cholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatments

Cited by 331

Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment

Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Cited by 298

Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus

Ashraf, G., Greig, N., Khan, T., Hassan, I., Tabrez, S., Shakil, S., Sheikh, I., Zaidi, S., Akram, M., Jabir, N., et al. (2014) · CNS & Neurological Disorders - Drug Targets

Alzheimer's disease research and treatmentsPrion Diseases and Protein Misfolding

Cited by 236

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., et al. (2025) · The Lancet

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 181

A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway

Kim, D. S., Choi, H.-I., Wang, Y., Luo, Y., Hoffer, B. J., & Greig, N. H. (2017) · Cell Transplantation

Parkinson's Disease Mechanisms and TreatmentsDiabetes Treatment and Management

Cited by 136

Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease

Perry, T., & Greig, N. (2005) · Current Alzheimer Research

Alzheimer's disease research and treatmentsDiabetes Treatment and Management

Cited by 127

Physiological and Pathological Role of Alpha-synuclein in Parkinson’s Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element

Olivares, D., Huang, X., Branden, L., Greig, N. H., & Rogers, J. T. (2009) · International Journal of Molecular Sciences

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 93

Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease

Ray, B., Maloney, B., Sambamurti, K., Karnati, H. K., Nelson, P. T., Greig, N. H., & Lahiri, D. K. (2020) · Translational Psychiatry

Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative Diseases

Cited by 91

Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases

Reale, M., Greig, N., & Kamal, M. (2009) · Mini-Reviews in Medicinal Chemistry

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Cited by 82

Role of cytokines in the gene expression of amyloid β–protein precursor: Identification of a 5'-UTR-Binding nuclear factor and its implications in Alzheimer's disease

Lahiri, D. K., Chen, D., Vivien, D., Ge, Y.-W., Greig, N. H., & Rogers, J. T. (2003) · Journal of Alzheimer s Disease

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 81

Roles of p75NTR, Long-Term Depression, and Cholinergic Transmission in Anxiety and Acute Stress Coping

Martinowich, K., Schloesser, R. J., Lu, Y., Jimenez, D. V., Paredes, D., Greene, J. S., Greig, N. H., Manji, H. K., & Lu, B. (2012) · Biological Psychiatry

Neuroscience and Neuropharmacology ResearchStress Responses and Cortisol

Cited by 48

Microglia Drive Pockets of Neuroinflammation in Middle Age

Moca, E. N., Lecca, D., Hope, K. T., Etienne, F., Schaler, A. W., Espinoza, K., Chappell, M. S., Gray, D. T., Tweedie, D., Sidhu, S., et al. (2022) · The Journal of Neuroscience

Neuroinflammation and Neurodegeneration MechanismsGenetics, Aging, and Longevity in Model Organisms

Cited by 42

Diphtheria toxin induced but not CSF1R inhibitor mediated microglia ablation model leads to the loss of CSF/ventricular spaces in vivo that is independent of cytokine upregulation

Bedolla, A., Taranov, A., Luo, F., Wang, J., Turcato, F., Fugate, E. M., Greig, N. H., Lindquist, D. M., Crone, S. A., Goto, J., et al. (2022) · Journal of Neuroinflammation

Neuroinflammation and Neurodegeneration MechanismsCerebrospinal fluid and hydrocephalus

Cited by 25